Ciclosporin liposomal - PARI Pharma

Drug Profile

Ciclosporin liposomal - PARI Pharma

Alternative Names: Ciclosporin inhalation - PARI Pharma; L-CsA - PARI Pharma

Latest Information Update: 03 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PARI
  • Developer Breath Therapeutics
  • Class Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Neuroprotectants
  • Mechanism of Action Calcineurin inhibitors; Free radical inhibitors; Immunosuppressants; Mitochondrial permeability transition pore inhibitors; P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bronchiolitis obliterans
  • New Molecular Entity No

Highest Development Phases

  • Phase III Bronchiolitis obliterans

Most Recent Events

  • 20 Mar 2017 Phase-II clinical trials in Bronchiolitis Obliterans in United Kingdom (Inhalation)
  • 20 Mar 2017 Phase-III clinical trials in Bronchiolitis Obliterans (Prevention) in Austria (Inhalation)
  • 20 Mar 2017 Phase-III clinical trials in Bronchiolitis Obliterans (Prevention) in Belgium (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top